These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22801803)

  • 1. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
    Vallo S; Mani J; Stastny M; Makarević J; Juengel E; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    Invest New Drugs; 2013 Apr; 31(2):265-72. PubMed ID: 22801803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
    Chuang MJ; Wu ST; Tang SH; Lai XM; Lai HC; Hsu KH; Sun KH; Sun GH; Chang SY; Yu DS; Hsiao PW; Huang SM; Cha TL
    PLoS One; 2013; 8(9):e73401. PubMed ID: 24023871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
    Ma Y; Liu W; Zhang L; Jia G
    Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
    Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
    Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
    Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells.
    Pettazzoni P; Pizzimenti S; Toaldo C; Sotomayor P; Tagliavacca L; Liu S; Wang D; Minelli R; Ellis L; Atadja P; Ciamporcero E; Dianzani MU; Barrera G; Pili R
    Free Radic Biol Med; 2011 Jan; 50(2):313-22. PubMed ID: 21078383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
    Yan-Fang T; Zhi-Heng L; Li-Xiao X; Fang F; Jun L; Gang L; Lan C; Na-Na W; Xiao-Juan D; Li-Chao S; Wen-Li Z; Pei-Fang X; He Z; Guang-Hao S; Yan-Hong L; Yi-Ping L; Yun-Yun X; Hui-Ting Z; Yi W; Mei-Fang J; Lin L; Jian N; Shao-Yan H; Xue-Ming Z; Xing F; Jian W; Jian P
    PLoS One; 2015; 10(7):e0126566. PubMed ID: 26176219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells.
    Xiao W; Graham PH; Hao J; Chang L; Ni J; Power CA; Dong Q; Kearsley JH; Li Y
    PLoS One; 2013; 8(8):e74253. PubMed ID: 23991216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
    BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
    Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
    Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases.
    Thakur VS; Gupta K; Gupta S
    Carcinogenesis; 2012 Feb; 33(2):377-84. PubMed ID: 22114073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
    Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
    Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
    Zhang L; Ma YP; Jia G
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):926-31. PubMed ID: 23363750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
    Woods DM; Woan K; Cheng F; Wang H; Perez-Villarroel P; Lee C; Lienlaf M; Atadja P; Seto E; Weber J; Sotomayor EM; Villagra A
    Melanoma Res; 2013 Oct; 23(5):341-8. PubMed ID: 23963286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma.
    Jeon YJ; Ko SM; Cho JH; Chae JI; Shim JH
    Int J Mol Med; 2013 Oct; 32(4):860-6. PubMed ID: 23877235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.
    Song X; Wang J; Zheng T; Song R; Liang Y; Bhatta N; Yin D; Pan S; Liu J; Jiang H; Liu L
    Mol Cancer; 2013 Oct; 12(1):114. PubMed ID: 24093956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
    Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.
    Wedel S; Hudak L; Seibel JM; Juengel E; Oppermann E; Haferkamp A; Blaheta RA
    Prostate; 2011 May; 71(7):722-35. PubMed ID: 20954195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.